Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Board Change

7 Sep 2010 07:01

RNS Number : 2408S
Genus PLC
07 September 2010
Β 

ο»Ώ

For immediate release 7 September 2010

Β 

Genus plc

("Genus" or "the Company")

Β 

Board Change

Β 

Β 

Genus, a leading global animal genetics company, is pleased to announce that Bob Lawson will become non-executive Chairman following the Company's Annual General Meeting on 11 November 2010 when John Hawkins, the present Chairman, will retire from the Board having served ten years as a non-executive director of the Company and six years as Chairman.

Β 

Bob Lawson, 65, is non-executive Chairman of Barratt Developments plc and is shortly to retire as Chairman of Hays plc. He is also a director of The Federation of Groundwork Trusts. His career has spanned several United Kingdom and continental groups including 10 years as Chief Executive of Electrocomponents plc leading its successful expansion into new international markets and three years as Managing Director of Vitec Group plc.

Β 

Bob Lawson said:

Β 

"I am excited at the potential of Genus' opportunities for growth, its world leading technology and the way this technology will be able to help increase food production for an increasing global population."

Β 

John Hawkins, Chairman, commented:

Β 

"I joined the Genus Board ten years ago. In that time, Genus has achieved tremendous growth with profits up tenfold. As I approach the end of my second three year term as Chairman, I have decided that the time is right for me to hand over leadership of the Board as Genus enters its next exciting phase of growth. Following an external search, I am pleased that Bob Lawson has accepted the Board's invitation to succeed me as Chairman from the conclusion of this year's Annual General Meeting. Bob has excellent experience in international markets and in chairing major companies and I wish him and Genus every success in the future.

Β 

I look back with pride on what Genus has achieved over the last ten years and I am certain the business will go from strength to strength in the years ahead."

Β 

Richard Wood, Chief Executive, said:

Β 

"On behalf of the Board, I would like to thank John for his considerable contribution over his ten years with Genus. John has overseen a transformation of the Company from its original flotation on AIM to becoming a truly global FTSE250 company and he has been instrumental in the expansion of Genus worldwide."

Β 

"I am delighted to welcome Bob Lawson to Genus. He will bring substantial experience to the Board, particularly in international markets. I look forward to working with him as we continue our strategic focus on growth in both developed and the developing markets."

Β 

Bob Lawson will chair the Company's Nomination Committee and be a member of the Company's Remuneration Committee. No further information is required to be disclosed in relation to Bob Lawson pursuant to LR 9.6.13 R.

Β 

For further information please contact:

Genus plc

Tel: 01256 345970

John Hawkins, Chairman

Richard Wood, Chief Executive

Buchanan Communications

Tel: 020 7466 5000

Charles Ryland, Suzanne Brocks

Β 

Β 

About Genus

Β 

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Β 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality, and use these to supply the global dairy and meat supply chain.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

Β 

Headquartered in Basingstoke, England, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAFMGGLVVVGGZM
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.